<DOC>
	<DOCNO>NCT00040300</DOCNO>
	<brief_summary>The purpose study evaluate Racivir . The safety , effective dosage , body reacts Racivir study .</brief_summary>
	<brief_title>A 14-Day Study Racivir When Used Combination HIV-Infected Males</brief_title>
	<detailed_description>The study 14-day study 21-day follow-up period . During 14-days active study period , participant receive Racivir daily combination efavirenz stavudine . Following administration first last dose study medication , patient remain clinic overnight . During study medical medication history take , physical examination , vital sign measurement , EKGs , routine clinical laboratory test .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Racivir</mesh_term>
	<criteria>Inclusion Criteria Subjects may eligible participate : Are male HIV infection positive HIV antibody test Have HIVRNA copy number ≥ 5000 copies/ml ( Roche assay ) Have CD4+ cell count ≥ 50 cells/ml Are 1845 year age , inclusive Have body mass index ( BMI ) ≥ 18 kg/m2 Are antiretroviral nucleoside reverse transcriptase inhibitornaive Have read understand inform consent , able willing comply study procedure Exclusion Criteria Subjects may participate : Have clinically significant ECG abnormality Have clinically significant abnormality safety laboratory parameter Have ALT value ≥ 3xUNL Have previously participate trial Have participate another trial investigational drug within last 3 month currently participate another trial investigational drug Have history chronic alcohol drug abuse within last 6 month Have positive urine drug screen Have positive alcohol breath test Have medical psychiatric condition , opinion investigator would jeopardize compromise subject ’ ability participate trial Have know hypersensitivity component trial medication comparative drug state protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>treatment experience</keyword>
	<keyword>HIV</keyword>
	<keyword>Phase I</keyword>
	<keyword>Combination Therapy</keyword>
</DOC>